Bottinger K, Regl C, Schapertons V, Rapp E, Wohlschlager T, Huber C
J Pharm Anal. 2025; 14(10):100982.
PMID: 39850237
PMC: 11755342.
DOI: 10.1016/j.jpha.2024.100982.
Cvijic T, Horvat M, Plahutnik J, Golob A, Marusic J
MAbs. 2024; 16(1):2430295.
PMID: 39572418
PMC: 11587841.
DOI: 10.1080/19420862.2024.2430295.
Liang G, Sha S, Wang Z, Liu H, Yoon S
Front Mol Biosci. 2024; 11:1441885.
PMID: 39502716
PMC: 11535473.
DOI: 10.3389/fmolb.2024.1441885.
Ramstrom M, Laven M, Amini A, Holst B
Sci Rep. 2024; 14(1):20861.
PMID: 39242599
PMC: 11379866.
DOI: 10.1038/s41598-024-71352-z.
Cheng Q, Farbiak L, Vaidya A, Guerrero E, Lee E, Rose E
Proc Natl Acad Sci U S A. 2023; 120(52):e2313009120.
PMID: 38109533
PMC: 10756300.
DOI: 10.1073/pnas.2313009120.
A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.
Niazi S
Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004421
PMC: 10675618.
DOI: 10.3390/ph16111556.
Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?.
Marschall L, Gottimukkala C, Kayal B, Veeraraghavan V, Mandal S, Bandyopadhyay S
Bioengineering (Basel). 2023; 10(10).
PMID: 37892879
PMC: 10603922.
DOI: 10.3390/bioengineering10101149.
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?.
Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S
BioDrugs. 2023; 37(6):855-871.
PMID: 37831324
PMC: 10581956.
DOI: 10.1007/s40259-023-00631-4.
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective.
Cohen H, Turner M, McCabe D, Woollett G
BioDrugs. 2023; 37(5):583-593.
PMID: 37542600
PMC: 10432323.
DOI: 10.1007/s40259-023-00619-0.
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies.
Hatfield G, Tepliakova L, Tran J, Lu H, Gilbert M, Tam R
MAbs. 2023; 15(1):2239405.
PMID: 37497986
PMC: 10376915.
DOI: 10.1080/19420862.2023.2239405.
Consistency of Product Quality for SB5, an Adalimumab Biosimilar.
Lee J, Lee N, Seo Y, Kim I
BioDrugs. 2023; 37(2):271-277.
PMID: 36719640
PMC: 9971099.
DOI: 10.1007/s40259-023-00581-x.
Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
Kumar P, Vuyyuru S, Kante B, Kedia S, Sahu P, Ranjan M
Indian J Gastroenterol. 2022; 41(5):446-455.
PMID: 36378484
DOI: 10.1007/s12664-022-01252-5.
Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
Robinson J, Md Yusof M, Davies V, Wild D, Morgan M, Taylor J
EBioMedicine. 2022; 86:104343.
PMID: 36371989
PMC: 9663864.
DOI: 10.1016/j.ebiom.2022.104343.
Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform.
Kang C, Lee S, Ahn T, Seo D, Ko B, Jung M
Sci Rep. 2022; 12(1):19030.
PMID: 36347901
PMC: 9643331.
DOI: 10.1038/s41598-022-23311-9.
The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.
Woollett G, Park J, Han J, Jung B
Clin Pharmacol Ther. 2022; 113(1):50-54.
PMID: 36148870
PMC: 10092046.
DOI: 10.1002/cpt.2753.
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.
Mayden K, Kelton J, Ryan J, McBride A
J Adv Pract Oncol. 2022; 13(4):417-439.
PMID: 35755898
PMC: 9214965.
DOI: 10.6004/jadpro.2022.13.4.5.
Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China.
Yao B, Zhang D, Cao W, Yang G, Li W, Hui X
Biomed Res Int. 2022; 2022:7868391.
PMID: 35535043
PMC: 9078787.
DOI: 10.1155/2022/7868391.
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.
Correia Pinheiro L, Giezen T, Wolff-Holz E, Weise M, Laslop A, Hidalgo-Simon A
Clin Pharmacol Ther. 2021; 110(5):1311-1317.
PMID: 34472087
PMC: 9292214.
DOI: 10.1002/cpt.2411.
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance.
Webster C, George K, Woollett G
BioDrugs. 2021; 35(4):379-387.
PMID: 34143406
PMC: 8295099.
DOI: 10.1007/s40259-021-00488-5.
Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics.
Pang K, Tay S, Wan C, Walsh I, Choo M, Yang Y
Front Chem. 2021; 9:661406.
PMID: 34084765
PMC: 8167043.
DOI: 10.3389/fchem.2021.661406.
